TCGA-AR-A0TQ-01A-11R-A084-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 100
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.620
- E2F_TARGETS+0.530
- G2M_CHECKPOINT+0.500
- INTERFERON_GAMMA_RESPONSE+0.480
- MTORC1_SIGNALING+0.420
- MITOTIC_SPINDLE+0.370
- CHOLESTEROL_HOMEOSTASIS+0.350
- UNFOLDED_PROTEIN_RESPONSE+0.350
- ALLOGRAFT_REJECTION+0.340
- ESTROGEN_RESPONSE_LATE+0.300
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.290
- NOTCH_SIGNALING-0.270
- WNT_BETA_CATENIN_SIGNALING-0.170
- COAGULATION-0.120
- PANCREAS_BETA_CELLS-0.120
- HEME_METABOLISM-0.110
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.100
- MYOGENESIS-0.070
- APICAL_JUNCTION-0.060
- P53_PATHWAY-0.060
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR15069615 | — | — | 0.880 |
| 2 | TCGA-XF-AAN2-01A-11R-A42T-07 | — | — | 0.837 |
| 3 | TCGA-A8-A09I-01A-22R-A034-07 | — | C | 0.831 |
| 4 | C3N-03764 | — | cohortA1 | 0.797 |
| 5 | DRR168600 | — | — | 0.795 |
| 6 | R328 | — | — | 0.793 |
| 7 | 8b88f1a0-d67d-4400-95c1-dc00ceb8b15f | — | — | 0.789 |
| 8 | MNG533 | — | — | 0.788 |
| 9 | TCGA-XF-A8HE-01A-11R-A36F-07 | — | — | 0.787 |
| 10 | AUR-AE5G-TTP1-A-1-1-R-A742-41 | — | C | 0.785 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.620 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.530 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.480 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.420 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.370 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.350 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.350 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.340 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.300 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.270 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.240 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.240 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.230 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.210 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.180 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.180 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.180 | Inavolisib | — uncovered |